We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
PVRI 2025 Rio: Embracing Heterogeneity
Our PVRI 2025 Annual Congress 'PVRI 2025 Rio: Embracing Heterogeneity' will be hosted in the vibrant and captivating city of Rio de Janeiro. Taking place 29 January - 1 February 2025, register your place today.
New for our Annual Congress, we will be hosting a Career Catalyst Luncheon to support early career professionals and trainees to connect with globally renowned senior and mid-career PH professionals in a welcoming and informal setting.
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
We are excited to announce that registrations are now open for the PVRI Drug Discovery and Development Symposium 2025! #DDDS2025 will be taking place 16-17 June 2025 in Amsterdam. See our event page for more details and register your place!
Webinar presentations: Scientific networks bridging pathogens and pulmonary vascular disease; Inflammasome activation in pulmonary arterial hypertension; CXCL12, endothelial cell metabolism, and endothelial proliferation in pulmonary arterial hypertension; Targeting neuroinflammation as a novel therapeutic strategy for pulmonary arterial hypertension and right heart failure; Spironolactone: an old drug with new tricks; HIPPO/MST signaling via BUB3 and FOXO drives pulmonary vascular cell growth and survival
Webinar presentations: Hispanic ethnicity and social determinants of health in pulmonary arterial hypertension; Sirtuin 3 and uncoupling protein2, the missing link between genetics, metabolism, and pulmonary arterial hypertension; Estrogen and portopulmonary hypertension: the Pulmonary Vascular Complications of Liver Disease Study; The right heart network and risk stratification in pulmonary arterial hypertension; Pulmonary hypertension caused by autocrine endothelial signaling
Patients with borderline pulmonary hypertension (PH) often experience shortness of breath or exacerbation of PH during exercise, known as exercise-induced PH. However, the pathogenesis of exercise-induced post-capillary PH (post-EIPH) and its treatment strategies remain unclear.
The right ventricular stroke work index (RVSWI) reflects the active work of the right ventricle (RV), but its clinical usefulness is not yet fully known in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
Pulmonary veno-occlusive disease (PVOD) is a lethal variant of pulmonary hypertension. The degree of pulmonary arterial involvement varies. Here, we compare two PVOD patients who were transplanted at 8 years of age, whereof one is a homozygous EIF2AK4 mutation carrier.
We are excited to announce that registrations are now open for the PVRI Drug Discovery and Development Symposium 2025! #DDDS2025 will be taking place 16-17 June 2025 in Amsterdam and promises to be an excellent opportunity for regulatory, industry, and academic bodies to meet and discuss the latest drug developments in PH.
On 27 September 2024, phase 1 of the Pulmonary Hypertension Global Patient Survey (PH GPS) closed. The survey was first launched in October 2023 to help clinicians better understand the impacts of PH on patients.
This World Heart Day, PVRI supports the WHF campaign calling for increased awareness, better healthcare policies and more funding for heart health research.
